1[1]Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. Journal of Clinical Epidemiology, 2003, 56 : 164 ～ 170 被引量：1
2[2]Caro J, Ward A, Levinton C, et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. Journal of Clinical Psychiatry, 2002, 63 : 1135 ～9 被引量：1
3[3]Cohen S, Fitzgerlad B, Okos A, et al. Weight, lipids, glucose and behavioral measures with ziprasidone treatment in a population with mental retardation. Journal of Clinical Psychiatry, 2003, 64: 60 ～ 2 被引量：1
4[4]de Vegt F, Dekker JM, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population. The Hoorn Study. JAMA, 2001, 285 : 2109 ～ 13 被引量：1
5[5]Gerstein HC, Pais P, et al. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. Journal of the American College of Cardiology, 1999, 33 : 612 ～9 被引量：1
6[6]Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database. J Clin Psychiatry, 2002, 63 : 920 ～ 930 被引量：1
7[7]Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety.Expert Opinion on Pharmacotherapy, 2002, 3 : 1773 ～81 被引量：1
8[8]Hagg S, Joelsson L, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. Journal of Clinical Psychiatry, 1998, 59: 294～9 被引量：1
9[9]Hedenmalm K, Hagg S, Stahl M, et al. Glucose intolerance with atypical antipsyehotics. Drug Saf, 2002, 25 : 1107 ～ 1116 被引量：1
10[10]Heiskanen T, Niskanen L, et al. Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry, 2003, 64 (5) : 575 ～9 被引量：1
